ArticleBlood cancer journal2026

Preclinical and clinical efficacy of the HDAC6 inhibitor ricolinostat in combination with BCR pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia.

Stephen P Martindale et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.